{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:15:36Z","timestamp":1793312136573,"version":"4.5.0"},"reference-count":144,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","award":["CSTB2022NSCQ-MSX1460"],"award-info":[{"award-number":["CSTB2022NSCQ-MSX1460"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573500"],"award-info":[{"award-number":["82573500"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iLIVER"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.iliver.2026.100243","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:45:26Z","timestamp":1778283926000},"page":"100243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting tumor-associated macrophages in pancreatic cancer"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7109-0156","authenticated-orcid":false,"given":"Yuxi","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luoyingzi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuming","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaizhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3489-4386","authenticated-orcid":false,"given":"Lei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.iliver.2026.100243_bib1","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","article-title":"Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention","volume":"164","author":"Stoffel","year":"2023","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.iliver.2026.100243_bib2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","article-title":"Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors","volume":"18","author":"Klein","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.iliver.2026.100243_bib3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.iliver.2026.100243_bib4","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and opportunities for pancreatic cancer immunotherapy","volume":"38","author":"Bear","year":"2020","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.iliver.2026.100243_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","article-title":"Therapeutic developments in pancreatic cancer","volume":"21","author":"Hu","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.iliver.2026.100243_bib6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41571-019-0281-6","article-title":"From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer","volume":"17","author":"Nevala-Plagemann","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"10.1016\/j.iliver.2026.100243_bib7","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr Biol"},{"key":"10.1016\/j.iliver.2026.100243_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12630","article-title":"ATRA mechanically reprograms pancreatic stellate cells to suppress matrix remodelling and inhibit cancer cell invasion","volume":"7","author":"Chronopoulos","year":"2016","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.iliver.2026.100243_bib9","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3390\/cancers11111627","article-title":"Myeloid-derived suppressor cells and pancreatic cancer: implications in novel therapeutic approaches","volume":"11","author":"Thyagarajan","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.iliver.2026.100243_bib10","article-title":"Immunotherapy: reshape the tumor immune microenvironment","volume":"13","author":"Lv","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.iliver.2026.100243_bib11","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41422-019-0195-y","article-title":"Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma","volume":"29","author":"Peng","year":"2019","journal-title":"Cell Res"},{"issue":"2","key":"10.1016\/j.iliver.2026.100243_bib12","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/j.jss.2009.05.026","article-title":"Significance of M2-polarized tumor-associated macrophage in pancreatic cancer","volume":"167","author":"Kurahara","year":"2011","journal-title":"J Surg Res"},{"key":"10.1016\/j.iliver.2026.100243_bib13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3389\/fphys.2013.00210","article-title":"Immune infiltrates as predictive markers of survival in pancreatic cancer patients","volume":"4","author":"Protti","year":"2013","journal-title":"Front Physiol"},{"issue":"1","key":"10.1016\/j.iliver.2026.100243_bib14","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/00006676-200401000-00023","article-title":"CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma","volume":"28","author":"Fukunaga","year":"2004","journal-title":"Pancreas"},{"key":"10.1016\/j.iliver.2026.100243_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1237711","article-title":"Roles of differently polarized macrophages in the initiation and progression of pancreatic cancer","volume":"14","author":"Storz","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.iliver.2026.100243_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12943-021-01313-x","article-title":"Non-coding RNAs regulation of macrophage polarization in cancer","volume":"20","author":"Mohapatra","year":"2021","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.iliver.2026.100243_bib17","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1038\/s41467-019-11911-5","article-title":"Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat Commun"},{"issue":"23","key":"10.1016\/j.iliver.2026.100243_bib18","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1158\/1078-0432.CCR-22-1125","article-title":"Neoadjuvant chemotherapy is associated with altered immune cell infiltration and an anti-tumorigenic microenvironment in resected pancreatic cancer","volume":"28","author":"Dias Costa","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.iliver.2026.100243_bib19","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/1078-0432.CCR-20-3141","article-title":"Composition, spatial characteristics, and prognostic significance of myeloid cell infiltration in pancreatic cancer","volume":"27","author":"V\u00e4yrynen","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.iliver.2026.100243_bib20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jnci\/djaa073","article-title":"Tumor microenvironment immune response in pancreatic ductal adenocarcinoma patients treated with neoadjuvant therapy","volume":"113","author":"Michelakos","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.iliver.2026.100243_bib21","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41590-023-01579-x","article-title":"Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC","volume":"24","author":"Baer","year":"2023","journal-title":"Nat Immunol"},{"key":"10.1016\/j.iliver.2026.100243_bib22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev-immunol-101320-031555","article-title":"Functional hallmarks of healthy macrophage responses: their regulatory basis and disease relevance","volume":"40","author":"Sheu","year":"2022","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"10.1016\/j.iliver.2026.100243_bib23","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1002\/jcp.26429","article-title":"Macrophage plasticity, polarization, and function in health and disease","volume":"233","author":"Shapouri-Moghaddam","year":"2018","journal-title":"J Cell Physiol"},{"issue":"22","key":"10.1016\/j.iliver.2026.100243_bib24","first-page":"23217","article-title":"Alteration of tumor-associated macrophage subtypes mediated by KRT6A in pancreatic ductal adenocarcinoma","volume":"12","author":"Zhang","year":"2020","journal-title":"Aging"},{"issue":"1","key":"10.1016\/j.iliver.2026.100243_bib25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12885-023-10597-9","article-title":"Immune landscape and prognostic index for pancreatic cancer based on TCGA database and in vivo validation","volume":"23","author":"Xu","year":"2023","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.iliver.2026.100243_bib26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.immuni.2005.10.001","article-title":"Macrophage polarization comes of age","volume":"23","author":"Mantovani","year":"2005","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.iliver.2026.100243_bib27","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/0008-5472.CAN-20-2990","article-title":"Macrophage-based approaches for cancer immunotherapy","volume":"81","author":"Anderson","year":"2021","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.iliver.2026.100243_bib28","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.it.2004.09.015","article-title":"The chemokine system in diverse forms of macrophage activation and polarization","volume":"25","author":"Mantovani","year":"2004","journal-title":"Trends Immunol"},{"key":"10.1016\/j.iliver.2026.100243_bib29","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9582430","article-title":"Macrophages and their role in atherosclerosis: pathophysiology and transcriptome analysis","volume":"2016","author":"Bobryshev","year":"2016","journal-title":"Biomed Res Int"},{"issue":"4","key":"10.1016\/j.iliver.2026.100243_bib30","doi-asserted-by":"crossref","first-page":"645","DOI":"10.5009\/gnl210311","article-title":"CD40 agonists alter the pancreatic cancer microenvironment by shifting the macrophage phenotype toward M1 and suppress human pancreatic cancer in organotypic slice cultures","volume":"16","author":"Lim","year":"2022","journal-title":"Gut Liver"},{"key":"10.1016\/j.iliver.2026.100243_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216457","article-title":"A novel role of TGFBI in macrophage polarization and macrophage-induced pancreatic cancer growth and therapeutic resistance","volume":"578","author":"Zhou","year":"2023","journal-title":"Cancer Lett"},{"issue":"3","key":"10.1016\/j.iliver.2026.100243_bib32","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.ymthe.2020.11.024","article-title":"M2 macrophage-derived exosomes promote angiogenesis and growth of pancreatic ductal adenocarcinoma by targeting E2F2","volume":"29","author":"Yang","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.iliver.2026.100243_bib33","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s13046-023-02890-z","article-title":"SNHG17 alters anaerobic glycolysis by resetting phosphorylation modification of PGK1 to foster pro-tumor macrophage formation in pancreatic ductal adenocarcinoma","volume":"42","author":"Lin","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"issue":"530","key":"10.1016\/j.iliver.2026.100243_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax6337","article-title":"Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses","volume":"12","author":"Jaynes","year":"2020","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.iliver.2026.100243_bib35","doi-asserted-by":"crossref","first-page":"7493","DOI":"10.3390\/ijms24087493","article-title":"Tumor-associated macrophage subsets: shaping polarization and targeting","volume":"24","author":"Zhang","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.iliver.2026.100243_bib36","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrgastro.2017.12","article-title":"Acinar cell plasticity and development of pancreatic ductal adenocarcinoma","volume":"14","author":"Storz","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.iliver.2026.100243_bib37","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ccr.2012.10.025","article-title":"Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma","volume":"22","author":"Kopp","year":"2012","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.iliver.2026.100243_bib38","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.celrep.2017.04.052","article-title":"The presence of interleukin-13 at pancreatic ADM\/PanIN lesions alters macrophage populations and mediates pancreatic tumorigenesis","volume":"19","author":"Liou","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.iliver.2026.100243_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120546","article-title":"Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment","volume":"268","author":"Zhou","year":"2021","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.iliver.2026.100243_bib40","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/cancers14010194","article-title":"Macrophage and neutrophil interactions in the pancreatic tumor microenvironment drive the pathogenesis of pancreatic cancer","volume":"14","author":"Pratt","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.iliver.2026.100243_bib41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/SHK.0000000000000820","article-title":"M2A and M2C macrophage subsets ameliorate inflammation and fibroproliferation in acute lung injury through interleukin 10 pathway","volume":"48","author":"Tang","year":"2017","journal-title":"Shock"},{"issue":"3","key":"10.1016\/j.iliver.2026.100243_bib42","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/JLB.6A1120-744R","article-title":"Use of integrated metabolomics, transcriptomics, and signal protein profile to characterize the effector function and associated metabotype of polarized macrophage phenotypes","volume":"111","author":"Anders","year":"2022","journal-title":"J Leukoc Biol"},{"issue":"8","key":"10.1016\/j.iliver.2026.100243_bib43","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41423-023-01047-4","article-title":"A subpopulation of CD146+ macrophages enhances antitumor immunity by activating the NLRP3 inflammasome","volume":"20","author":"Jing","year":"2023","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"10.1016\/j.iliver.2026.100243_bib44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.iliver.2026.100243_bib45","article-title":"Tumor-associated macrophages in pancreatic ductal adenocarcinoma: origin, polarization, function, and reprogramming","volume":"8","author":"Yang","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"10.1016\/j.iliver.2026.100243_bib46","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.3390\/cancers13122860","article-title":"Tumor-associated macrophages in pancreatic ductal adenocarcinoma: therapeutic opportunities and clinical challenges","volume":"13","author":"Poh","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.iliver.2026.100243_bib47","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s12672-025-02838-z","article-title":"Establishment of M2 macrophage-related prognostic signature in pancreatic ductal adenocarcinoma","volume":"16","author":"Chen","year":"2025","journal-title":"Discov Oncol"},{"key":"10.1016\/j.iliver.2026.100243_bib48","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","article-title":"Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments","volume":"10","author":"Xu","year":"2025","journal-title":"Signal Transduct Targeted Ther"},{"issue":"5","key":"10.1016\/j.iliver.2026.100243_bib50","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2024.03.009","article-title":"The crosstalk between macrophages and cancer cells potentiates pancreatic cancer Cachexia","volume":"42","author":"Liu","year":"2024","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.iliver.2026.100243_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004032","article-title":"In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies","volume":"10","author":"Ieran\u00f2","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.iliver.2026.100243_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003982","article-title":"Combination cancer immunotherapy targeting TNFR2 and PD-1\/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors","volume":"10","author":"Zhang","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"31","key":"10.1016\/j.iliver.2026.100243_bib51","doi-asserted-by":"crossref","first-page":"50735","DOI":"10.18632\/oncotarget.9383","article-title":"Targeting tumor-associated macrophages to combat pancreatic cancer","volume":"7","author":"Cui","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.iliver.2026.100243_bib52","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/gutjnl-2021-325564","article-title":"Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma","volume":"72","author":"Alonso-Nocelo","year":"2023","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.iliver.2026.100243_bib53","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ccell.2023.04.018","article-title":"Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"issue":"7986","key":"10.1016\/j.iliver.2026.100243_bib54","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41586-023-06685-2","article-title":"IL-1\u03b2+ macrophages fuel pathogenic inflammation in pancreatic cancer","volume":"623","author":"Caronni","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.iliver.2026.100243_bib55","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41392-021-00769-z","article-title":"Pancreatic cancer cells render tumor-associated macrophages metabolically reprogrammed by a GARP and DNA methylation-mediated mechanism","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct Targeted Ther"},{"issue":"6","key":"10.1016\/j.iliver.2026.100243_bib56","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.21037\/gs-20-828","article-title":"FOLFIRINOX regulated tumor immune microenvironment to extend the survival of patients with resectable pancreatic ductal adenocarcinoma","volume":"9","author":"Wu","year":"2020","journal-title":"Gland Surg"},{"issue":"2","key":"10.1016\/j.iliver.2026.100243_bib58","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.iliver.2026.100243_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-023-01388-7","article-title":"Macrophages reprogramming driven by cancer-associated fibroblasts under FOLFIRINOX treatment correlates with shorter survival in pancreatic cancer","volume":"22","author":"Hussain","year":"2024","journal-title":"Cell Commun Signal"},{"issue":"1","key":"10.1016\/j.iliver.2026.100243_bib59","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12672-024-01256-x","article-title":"The complex role of macrophages in pancreatic cancer tumor microenvironment: a review on cancer progression and potential therapeutic targets","volume":"15","author":"Lorestani","year":"2024","journal-title":"Discov Oncol"},{"issue":"7890","key":"10.1016\/j.iliver.2026.100243_bib60","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.iliver.2026.100243_bib62","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12943-023-01900-0","article-title":"Acidosis-mediated increase in IFN-\u03b3-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors","volume":"22","author":"Knopf","year":"2023","journal-title":"Mol Cancer"},{"issue":"16","key":"10.1016\/j.iliver.2026.100243_bib63","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","article-title":"Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity","volume":"187","author":"Cillo","year":"2024","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.iliver.2026.100243_bib64","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.iliver.2026.100243_bib65","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.ymthe.2024.09.026","article-title":"PD-L1: from cancer immunotherapy to therapeutic implications in multiple disorders","volume":"32","author":"Lee","year":"2024","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.iliver.2026.100243_bib66","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.jaci.2018.12.995","article-title":"Macrophage polarization: reaching across the aisle?","volume":"143","author":"Bosco","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iliver.2026.100243_bib67","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","article-title":"Autoimmune chronic spontaneous urticaria","volume":"149","author":"Kolkhir","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.iliver.2026.100243_bib68","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1164\/rccm.202307-1266OC","article-title":"Increased Muc5AC and decreased ciliated cells in severe asthma partially restored by inhibition of IL-4R\u03b1 receptor","volume":"210","author":"Boomer","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"55","key":"10.1016\/j.iliver.2026.100243_bib69","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abe2749","article-title":"Persistence of mature dendritic cells, TH2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4R\u03b1 blockade","volume":"6","author":"Bangert","year":"2021","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.iliver.2026.100243_bib70","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"10.1016\/j.iliver.2026.100243_bib71","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc\u2019h","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.iliver.2026.100243_bib72","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2020.02.011","article-title":"Remodeling tumor immune microenvironment via targeted blockade of PI3K-\u03b3 and CSF-1\/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy","volume":"321","author":"Li","year":"2020","journal-title":"J Contr Release"},{"issue":"2","key":"10.1016\/j.iliver.2026.100243_bib73","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001153","article-title":"Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients","volume":"8","author":"Machiels","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"16","key":"10.1016\/j.iliver.2026.100243_bib74","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","article-title":"Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer","volume":"27","author":"Byrne","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.iliver.2026.100243_bib75","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cytogfr.2023.11.002","article-title":"Harnessing the potential of CD40 agonism in cancer therapy","volume":"75","author":"Zhou","year":"2024","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"10.1016\/j.iliver.2026.100243_bib76","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.immuni.2022.12.006","article-title":"Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages","volume":"56","author":"Tichet","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.iliver.2026.100243_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215751","article-title":"Exosome-derived FGD5-AS1 promotes tumor-associated macrophage M2 polarization-mediated pancreatic cancer cell proliferation and metastasis","volume":"548","author":"He","year":"2022","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.iliver.2026.100243_bib78","doi-asserted-by":"crossref","first-page":"194","DOI":"10.7150\/ijbs.39024","article-title":"Ruxolitinib alleviates renal interstitial fibrosis in UUO mice","volume":"16","author":"Bai","year":"2020","journal-title":"Int J Biol Sci"},{"issue":"3","key":"10.1016\/j.iliver.2026.100243_bib79","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jaci.2024.11.032","article-title":"Ruxolitinib treatment ameliorates clinical, immunologic, and transcriptomic aberrations in patients with STAT3 gain-of-function disease","volume":"155","author":"Bayram Catak","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"21","key":"10.1016\/j.iliver.2026.100243_bib80","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1158\/1078-0432.CCR-22-0744","article-title":"STAT3 activation as a predictive biomarker for ruxolitinib response in head and neck cancer","volume":"28","author":"Qureshy","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.iliver.2026.100243_bib81","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ccell.2020.06.007","article-title":"IL6\/STAT3 signaling hijacks estrogen receptor \u03b1 enhancers to drive breast cancer metastasis","volume":"38","author":"Siersb\u00e6k","year":"2020","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.iliver.2026.100243_bib82","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.7150\/ijbs.96489","article-title":"Ruxolitinib-based senomorphic therapy mitigates cardiomyocyte senescence in septic cardiomyopathy by inhibiting the JAK2\/STAT3 signaling pathway","volume":"20","author":"Yang","year":"2024","journal-title":"Int J Biol Sci"},{"issue":"2","key":"10.1016\/j.iliver.2026.100243_bib83","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41419-024-06511-1","article-title":"Ruxolitinib induces apoptosis and pyroptosis of anaplastic thyroid cancer via the transcriptional inhibition of DRP1-mediated mitochondrial fission","volume":"15","author":"Guo","year":"2024","journal-title":"Cell Death Dis"},{"issue":"34","key":"10.1016\/j.iliver.2026.100243_bib84","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1200\/JCO.2015.61.4578","article-title":"Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed","volume":"33","author":"Hurwitz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.iliver.2026.100243_bib85","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10637-018-0580-2","article-title":"Ruxolitinib + capecitabine in advanced\/metastatic pancreatic cancer after disease progression\/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies","volume":"36","author":"Hurwitz","year":"2018","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.iliver.2026.100243_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115326","article-title":"Bortezomib inhibits NLRP3 inflammasome activation and NF-\u03baB pathway to reduce psoriatic inflammation","volume":"206","author":"Chen","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.iliver.2026.100243_bib87","doi-asserted-by":"crossref","DOI":"10.1177\/11795549241239042","article-title":"Identification of transcriptomic signatures of pancreatic ductal adenocarcinoma-derived exosomes that promote macrophage M2 polarization and predict prognosis: S100A9 reveals tumor progression","volume":"18","author":"Tan","year":"2024","journal-title":"Clin Med Insights Oncol"},{"issue":"16","key":"10.1016\/j.iliver.2026.100243_bib88","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1158\/0008-5472.CAN-17-3841","article-title":"Hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN\/PI3K\u03b3 to promote pancreatic cancer metastasis","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.iliver.2026.100243_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102861","article-title":"PI3K\/AKT\/mTOR inhibitors for hormone receptor-positive advanced breast cancer","volume":"132","author":"Hao","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"23","key":"10.1016\/j.iliver.2026.100243_bib90","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1039\/D0SC01676D","article-title":"PI3K inhibitors: review and new strategies","volume":"11","author":"Zhang","year":"2020","journal-title":"Chem Sci"},{"issue":"10","key":"10.1016\/j.iliver.2026.100243_bib91","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","article-title":"PI3K inhibitors are finally coming of age","volume":"20","author":"Vanhaesebroeck","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.iliver.2026.100243_bib92","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.annonc.2020.05.001","article-title":"Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer","volume":"31","author":"Rugo","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.iliver.2026.100243_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13062-023-00356-y","article-title":"M2 macrophage-derived exosomal miR-193b-3p promotes progression and glutamine uptake of pancreatic cancer by targeting TRIM62","volume":"18","author":"Zhang","year":"2023","journal-title":"Biol Direct"},{"issue":"2","key":"10.1016\/j.iliver.2026.100243_bib94","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.immuni.2022.01.006","article-title":"Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity","volume":"55","author":"Hezaveh","year":"2022","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.iliver.2026.100243_bib95","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.iliver.2026.100243_bib96","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.iliver.2026.100243_bib97","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S1470-2045(15)00132-1","article-title":"CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study","volume":"16","author":"Cassier","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.iliver.2026.100243_bib98","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004076","article-title":"Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients na\u00efve or experienced for immune checkpoint blockade","volume":"10","author":"Gomez-Roca","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.iliver.2026.100243_bib99","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/annonc\/mdz163","article-title":"Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced\/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages","volume":"30","author":"Gomez-Roca","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.iliver.2026.100243_bib100","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.celrep.2018.03.131","article-title":"CSF1R+ macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype","volume":"23","author":"Candido","year":"2018","journal-title":"Cell Rep"},{"issue":"731","key":"10.1016\/j.iliver.2026.100243_bib101","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add1834","article-title":"The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers","volume":"16","author":"Voissi\u00e8re","year":"2024","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.iliver.2026.100243_bib102","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12974-023-02984-7","article-title":"CSF-1R inhibitor PLX3397 attenuates peripheral and brain chronic GVHD and improves functional outcomes in mice","volume":"20","author":"Shaikh","year":"2023","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.iliver.2026.100243_bib103","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.bbi.2024.09.016","article-title":"Microglial and neuronal fates following inhibition of CSF-1R in synucleinopathy mouse model","volume":"123","author":"Iba","year":"2025","journal-title":"Brain Behav Immun"},{"issue":"7","key":"10.1016\/j.iliver.2026.100243_bib104","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004784","article-title":"Toll-like receptor 7\/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer","volume":"10","author":"Ye","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.iliver.2026.100243_bib105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002408","article-title":"Intratumoral combination therapy with poly(I: C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity","volume":"9","author":"Anfray","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"13","key":"10.1016\/j.iliver.2026.100243_bib106","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.3390\/ijms25137500","article-title":"TLR agonists modify NK cell activation and increase its cytotoxicity in acute lymphoblastic leukemia","volume":"25","author":"Gallardo-Zapata","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.iliver.2026.100243_bib107","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-019-12657-w","article-title":"The TLR7\/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer","volume":"10","author":"Michaelis","year":"2019","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.iliver.2026.100243_bib108","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1021\/acs.accounts.9b00631","article-title":"Small-molecule modulators of toll-like receptors","volume":"53","author":"Wang","year":"2020","journal-title":"Acc Chem Res"},{"issue":"10","key":"10.1016\/j.iliver.2026.100243_bib109","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1021\/acs.jmedchem.2c01655","article-title":"Small-molecule modulators targeting toll-like receptors for potential anticancer therapeutics","volume":"66","author":"Wang","year":"2023","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.iliver.2026.100243_bib110","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011173","article-title":"Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer","volume":"13","author":"Adams","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.iliver.2026.100243_bib111","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/ni.1990","article-title":"IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses","volume":"12","author":"Krausgruber","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.iliver.2026.100243_bib112","article-title":"Advances in the study of TIM3 in myelodysplastic syndrome","volume":"16","author":"Guo","year":"2025","journal-title":"Front Immunol"},{"issue":"27","key":"10.1016\/j.iliver.2026.100243_bib113","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl5165","article-title":"Interrogating glioma-M2 macrophage interactions identifies Gal-9\/Tim-3 as a viable target against PTEN-null glioblastoma","volume":"8","author":"Ni","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.iliver.2026.100243_bib114","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","article-title":"Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.iliver.2026.100243_bib115","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1002\/ajh.27161","article-title":"Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes","volume":"99","author":"Brunner","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.iliver.2026.100243_bib116","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11912-022-01218-y","article-title":"New checkpoint inhibitors on the road: targeting TIM-3 in solid tumors","volume":"24","author":"Gomes de Morais","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"17","key":"10.1016\/j.iliver.2026.100243_bib117","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1158\/1078-0432.CCR-24-2131","article-title":"Correction: phase I\/ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors","volume":"30","author":"Curigliano","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.iliver.2026.100243_bib118","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","article-title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"11","author":"Zeidan","year":"2024","journal-title":"Lancet Haematol"},{"issue":"16","key":"10.1016\/j.iliver.2026.100243_bib119","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1158\/1078-0432.CCR-25-0884","article-title":"Combined targeting of PD-1 and TIM-3 in patients with locally advanced or metastatic melanoma: amber cohorts 1c, 1e, and 2A","volume":"31","author":"Davar","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.iliver.2026.100243_bib120","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1080\/15548627.2020.1714209","article-title":"Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein","volume":"16","author":"Dai","year":"2020","journal-title":"Autophagy"},{"issue":"16","key":"10.1016\/j.iliver.2026.100243_bib121","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1158\/0008-5472.CAN-22-3645","article-title":"Syk inhibition reprograms tumor-associated macrophages and overcomes gemcitabine-induced immunosuppression in pancreatic ductal adenocarcinoma","volume":"83","author":"Rohila","year":"2023","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.iliver.2026.100243_bib122","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.tips.2024.08.006","article-title":"New insights into SYK targeting in solid tumors","volume":"45","author":"Joshi","year":"2024","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.iliver.2026.100243_bib123","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41420-025-02342-x","article-title":"Syk inhibitor attenuates lupus in Fc\u03b3RIIb-\/- mice through the Inhibition of DNA extracellular traps from macrophages and neutrophils via p38MAPK-dependent pathway","volume":"11","author":"Sae-Khow","year":"2025","journal-title":"Cell Death Discov"},{"issue":"19","key":"10.1016\/j.iliver.2026.100243_bib124","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122430","article-title":"SYK inhibitor entospletinib prevents ocular and skin GVHD in mice","volume":"3","author":"Poe","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.iliver.2026.100243_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112636","article-title":"Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome","volume":"204","author":"Jorda","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"16","key":"10.1016\/j.iliver.2026.100243_bib126","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.189601","article-title":"The spleen tyrosine kinase inhibitor entospletinib resolves inflammation to promote repair following acute kidney injury","volume":"10","author":"Elias","year":"2025","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.iliver.2026.100243_bib127","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1164\/rccm.202110-2274OC","article-title":"Macrophage-NLRP3 activation promotes right ventricle failure in pulmonary arterial hypertension","volume":"206","author":"Al-Qazazi","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.iliver.2026.100243_bib128","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbi.2023.11.031","article-title":"MCC950 reduces autophagy and improves cognitive function by inhibiting NLRP3-dependent neuroinflammation in a rat model of Alzheimer\u2019s disease","volume":"116","author":"Naeem","year":"2024","journal-title":"Brain Behav Immun"},{"issue":"11","key":"10.1016\/j.iliver.2026.100243_bib129","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1136\/gutjnl-2023-331447","article-title":"Neutrophil extracellular traps activate hepatic stellate cells and monocytes via NLRP3 sensing in alcohol-induced acceleration of MASH fibrosis","volume":"73","author":"Babuta","year":"2024","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.iliver.2026.100243_bib130","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1021\/acs.jmedchem.4c02759","article-title":"Discovery of DFV890, a potent Sulfonimidamide-Containing NLRP3 inflammasome inhibitor","volume":"68","author":"Shen","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.iliver.2026.100243_bib131","article-title":"PET-MRI biomarkers reveal efficacy of a novel NLRP3 inhibitor in Parkinson\u2019s disease models","author":"Albornoz","year":"2025","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.iliver.2026.100243_bib132","article-title":"NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy","volume":"4","author":"Hurtado-Navarro","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.iliver.2026.100243_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104299","article-title":"Interleukin-1 and the NLRP3 inflammasome in COVID-19: pathogenetic and therapeutic implications","volume":"85","author":"Potere","year":"2022","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.iliver.2026.100243_bib134","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nri3073","article-title":"Protective and pathogenic functions of macrophage subsets","volume":"11","author":"Murray","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.iliver.2026.100243_bib135","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00011-024-01907-3","article-title":"Dissection of pro-tumoral macrophage subtypes and immunosuppressive cells participating in M2 polarization","volume":"73","author":"Sezginer","year":"2024","journal-title":"Inflamm Res"},{"issue":"4","key":"10.1016\/j.iliver.2026.100243_bib136","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1189\/jlb.0212107","article-title":"CCL1 released from M2b macrophages is essentially required for the maintenance of their properties","volume":"92","author":"Asai","year":"2012","journal-title":"J Leukoc Biol"},{"issue":"22","key":"10.1016\/j.iliver.2026.100243_bib137","doi-asserted-by":"crossref","first-page":"22508","DOI":"10.1021\/acsnano.3c05998","article-title":"Precisely regulating M2 subtype macrophages for renal fibrosis resolution","volume":"17","author":"Luo","year":"2023","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.iliver.2026.100243_bib138","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.iliver.2026.100243_bib139","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1411366","article-title":"Structure-Guided blockade of CSF1R kinase in tenosynovial giant-cell tumor","volume":"373","author":"Tap","year":"2015","journal-title":"N Engl J Med"},{"issue":"10197","key":"10.1016\/j.iliver.2026.100243_bib140","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.iliver.2026.100243_bib141","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.iliver.2026.100243_bib142","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1158\/1078-0432.CCR-13-0525","article-title":"Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2\/CCR2 axis","volume":"19","author":"Sanford","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.iliver.2026.100243_bib143","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.iliver.2026.100243_bib144","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/gut.2010.226092","article-title":"Stromal biology and therapy in pancreatic cancer","volume":"60","author":"Neesse","year":"2011","journal-title":"Gut"}],"container-title":["iLIVER"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772947826000277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772947826000277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:46:25Z","timestamp":1783104385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772947826000277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":144,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2772947826000277"],"URL":"https:\/\/doi.org\/10.1016\/j.iliver.2026.100243","relation":{},"ISSN":["2772-9478"],"issn-type":[{"value":"2772-9478","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting tumor-associated macrophages in pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"iLIVER","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iliver.2026.100243","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd on behalf of Tsinghua University Press.","name":"copyright","label":"Copyright"}],"article-number":"100243"}}